<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00667758</url>
  </required_header>
  <id_info>
    <org_study_id>R1/05</org_study_id>
    <secondary_id>2007/2/0174</secondary_id>
    <nct_id>NCT00667758</nct_id>
  </id_info>
  <brief_title>Gonadotropin-Releasing Hormone (GnRH)-Antagonist Therapy in Rheumatoid Arthritis</brief_title>
  <acronym>AGRA</acronym>
  <official_title>Antagonist to Gonadotropin-Releasing Hormone in Rheumatoid Arthritis (AGRA): A Double-blind, Randomized, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Betanien Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian Foundation for Health and Rehabilitation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Betanien Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of gonadotropin-releasing
      hormone (GnRH) antagonist therapy versus placebo in patients with moderate to severe
      rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Disease Activity Score (DAS28CRP) in cetrorelix group versus placebo group</measure>
    <time_frame>From baseline to day 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in DAS28 (CRP/ESR)</measure>
    <time_frame>From baseline to day 2/5 /10/15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anti-CCP level</measure>
    <time_frame>From baseline to day 2/5/10/15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cytokine level</measure>
    <time_frame>From baseline to day 2/5/10/15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ACR core set measures</measure>
    <time_frame>From baseline to day 2/5/10/15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ACR 20/50/70/90 and EULAR good/moderate/none responders</measure>
    <time_frame>Baseilne to day 2/5/10/15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Baseline up to day 15</time_frame>
    <description>Number of patients with adverse events (and serious adverse events) up to day 15 in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with DAS28low disease activity/remission</measure>
    <time_frame>Baseline to day 2/5/10/15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HAQ scores</measure>
    <time_frame>From baseline to day 5/10/15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between percent changes in hormones, disease activity and biomarkers</measure>
    <time_frame>By day 2, 5, 10 and 15</time_frame>
    <description>This endpoint is not directly related to clinical efficacy. Hormones include LH, FSH, oestradiol, testosterone,and cortisol. Biomarkers include immunologic markers, bone markers and cardiovascular markers. This secondary endpoint was sent to authorities during the study before unblinding.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetrorelix</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetrorelix</intervention_name>
    <description>3-5 mg s.c. on days 1-5</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3-5 ml NaCl s.c. on days 1-5</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult between 18 years and above

          -  Moderate to severe disease activity

          -  Negative pregnancy test for women of childbearing potential

          -  Use of reliable method of contraception (non-hormonal) by sexually active female
             patients

        Exclusion Criteria:

          -  Patients who are pregnant or breastfeeding

          -  Patients taking biologic therapy or prednisolone &gt;7.5mg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kåss</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oslo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deaprtment of Rheumatology, Betanien Hospital</name>
      <address>
        <city>Skien</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2008</study_first_posted>
  <last_update_submitted>August 3, 2012</last_update_submitted>
  <last_update_submitted_qc>August 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Betanien Hospital</investigator_affiliation>
    <investigator_full_name>Anita Kass</investigator_full_name>
    <investigator_title>Dr Anita Kåss</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Cetrorelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

